S'abonner

Cost Offset Associated With Early Start Denver Model for Children With Autism - 23/08/17

Doi : 10.1016/j.jaac.2017.06.007 
Zuleyha Cidav, PhD a, , Jeff Munson, PhD b, Annette Estes, PhD b, Geraldine Dawson, PhD c, Sally Rogers, PhD d, David Mandell, ScD a
a Center for Mental Health Policy and Services Research, University of Pennsylvania Perelman School of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia 
b University of Washington, Seattle 
c Duke Center for Autism and Brain Development, Duke University, Durham, NC 
d MIND Institute, University of California, Davis 

Correspondence to Zuleyha Cidav, PhD, Center for Mental Health Policy and Services Research, University of Pennsylvania Perelman School of Medicine, 3535 Market Street, 3rd Floor, Philadelphia, PA 19104Center for Mental Health Policy and Services ResearchUniversity of Pennsylvania Perelman School of Medicine3535 Market Street, 3rd FloorPhiladelphiaPA 19104

Abstract

Objective

To determine the effect of the Early Start Denver Model (ESDM) for treatment of young children with autism on health care service use and costs.

Method

We used data from a randomized trial that tested the efficacy of the ESDM, which is based on developmental and applied behavioral analytic principles and delivered by trained therapists and parents, for 2 years. Parents were interviewed about their children’s service use every 6 months from the onset of the intervention to follow-up (age 6 years). The sample for this study consisted of 39 children with autism who participated in the original randomized trial at age 18 to 30 months, and were also assessed at age 6 years. Of this sample, 21 children were in the ESDM group, and 18 children were in the community care (COM) group. Reported services were categorized and costed by applying unit hourly costs. Annualized service use and costs during the intervention and post intervention for the two study arms were compared.

Results

During the intervention, children who received the ESDM had average annualized total health-related costs that were higher by about $14,000 than those of children who received community-based treatment. The higher cost of ESDM was partially offset during the intervention period because children in the ESDM group used less applied behavior analysis (ABA)/early intensive behavioral intervention (EIBI) and speech therapy services than children in the comparison group. In the postintervention period, compared with children who had earlier received treatment as usual in community settings, children in the ESDM group used less ABA/EIBI, occupational/physical therapy, and speech therapy services, resulting in significant cost savings in the amount of about $19,000 per year per child.

Conclusion

Costs associated with ESDM treatment were fully offset within a few years after the intervention because of reductions in other service use and associated costs.

Clinical trial registration information: Early Characteristics of Autism; clinicaltrials.gov/; NCT0009415.

Le texte complet de cet article est disponible en PDF.

Key words : autism, cost, use, Early Start Denver Model, early intervention


Plan


 This article is discussed in an editorial by Dr. Douglas L. Leslie on page 727.
 The clinical trial was supported by National Institute of Mental Health grant U54MH066399 (Dawson, PI), which was registered at www.clinicaltrials.gov with identifier NCT00090415. Additional grants supported the long-term follow-up study (Estes, PI) funded by the National Institute of Child Health and Human Development (U19HD34565, P50HD066782, R01HD-55741), and the National Institute of Mental Health (U54MH066399). Autism Speaks also provided financial support.
 Dr. Cidav conceptualized the study and its design, conducted the analyses, and drafted the initial manuscript. Dr. Munson assisted with the analyses, especially the coding of different service types, and assisted with interpretation of data. Dr. Estes oversaw original data collection for the follow-up study, and assisted with acquisition and interpretation of data. Dr. Dawson designed and oversaw the original randomized controlled trial and its data collection, and assisted with the acquisition of data and interpretation of data. Dr. Rogers provided training and consultation on the original randomized controlled trial and assisted with interpretation of data. Dr. Mandell helped draft the initial manuscript, and assisted with analysis and interpretation of data. All authors assisted with revising the manuscript for important intellectual content, gave final approval of the version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
 Drs. Cidav and Munson served as the statistical experts for this research.
 Disclosure: Dr. Dawson has served on the scientific advisory boards of Janssen Research and Development and Akili, Inc., as a consultant to Roche, and has received grant funding from Janssen Research and Development, LLC and PerkinElmer. She has received royalties from the sale of the Early Start Denver Model manuals, Guilford Press, and Oxford University Press. Dr. Rogers has received royalties from the sale of the Early Start Denver Model manuals. Dr. Mandell has served on the scientific advisory board of the Autism Science Foundation and serves as the editor-in-chief of Autism: The International Journal of Research and Practice, for which he receives a stipend. Drs. Cidav, Munson, and Estes report no biomedical financial interests or potential conflicts of interest.


© 2017  American Academy of Child and Adolescent Psychiatry. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 56 - N° 9

P. 777-783 - septembre 2017 Retour au numéro
Article précédent Article précédent
  • Cross-Domain Symptom Development Typologies and Their Antecedents: Results From the UK Millennium Cohort Study
  • Praveetha Patalay, Vanessa Moulton, Alissa Goodman, George B. Ploubidis
| Article suivant Article suivant
  • Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study
  • Christoph U. Correll, Eva Kohegyi, Cathy Zhao, Ross A. Baker, Robert McQuade, Phyllis M. Salzman, Raymond Sanchez, Margaretta Nyilas, William Carson

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.